ClinicalTrials.gg
RecruitingNCT07073703FRAGECOUpdated Dec 9, 2025

Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.

An interventional study of APA and Therapeutic education workshops in Bladder (Urothelial, Transitional Cell) Cancer and Kidney (Renal Cell) Cancer, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 2 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Bladder and kidney cancers are commonly diagnosed in older adults. Surgery remains the primary treatment modality for patients with kidney or bladder cancer. In older patients, common co-morbidities include fatigue, physical deconditioning characterized by reduced cardiorespiratory fitness and progressing sarcopenia, pain- whether disease- related or treatment-induced- and undernutrition. These factors increased the risk of post-operative complications and exacerbate patient frailty.

The investigators propose a personalized 6-month program both pre- and post-surgery, including adapted physical activity sessions, therapeutic education workshops, and systematic referral to the department's DAPAP program.

02

Conditions studied

  • Bladder (Urothelial, Transitional Cell) Cancer
  • Kidney (Renal Cell) Cancer

Keywords

  • Exercise
  • Older people
  • Cancer
  • Bladder
  • Kidney
  • Frailty
  • Surgery
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 106 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of bladder or kidney cancer
  • Surgical treatment
  • No severe cognitive impairment preventing understanding of the protocol
  • Affiliated or entitled to a social security scheme
  • Having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Surgery already done
  • Significant co-morbidities that contraindicate physical activity: associated cardiac pathologies, respiratory pathologies, disabling joint pathologies, etc.
  • Deprived of liberty or under guardianship
  • Benefiting from a prehabilitation prescription with a private physiotherapist.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • No intervention
    Control group

    The control group will consist of patients with bladder or kidney cancer receiving standard care, which includes a comprehensive assessment by an oncogeriatrician followed by surgery approximately 4 weeks later. Postoperatively, patients will be transferred to a rehabilitation center (SSR) for recovery, in line with standard clinical practice. As part of the study protocol, control group patients will undergo additional follow-up assessments alongside their usual care. These follow-ups-conducted at baseline, and at 1, 2, 3 months, and at the final endpoint-will mirror those of the intervention group. They will include patients- completed questionnaires and physical assessments conducted by an adapted physical activity teacher.

  • Experimental
    Interventional group

    The interventional group will consist of bladder and kidney cancer patients who will follow a personalized 6-month care pathway in addition to standard care. This pathway includes: * 2 adapted physical activity (APA) sessions per week for 4 weeks prior to surgery * 2 APA sessions/ week for 4 weeks following surgery * Therapeutic education workshops tailored to individual needs, covering topics as physical activity, nutrition, treatments, fatigue, and relaxation * Referral to the department's DAPAP for a 12-week "bridge program", consisting of one APA session per week. The study will be conducted in the oncogeriatrics departments of Saint-Etienne University Hospital and Loire Private Hospital.

    Procedure: APA · Behavioral: Therapeutic education workshops · Procedure: DAPAP

Interventions

  • ProcedureAPA

    2 adapted physical activity (APA) sessions per week for 4 weeks before and after surgery

  • BehavioralTherapeutic education workshops

    Therapeutic education workshops tailored to individual needs, covering topics as physical activity, nutrition, treatments, fatigue, and relaxation.

  • ProcedureDAPAP

    Referral to the department's DAPAP for a 12-week "bridge program", consisting of one session per week.

06

What researchers measure

Primary outcomes

  1. Patient frailty

    Frailty will be measured using the walking distance (in metres) achieved during the 6-minute walk test (6MWT) 6 months after the patient's inclusion.

    Time frame: Day : 1 and Month : 6

Secondary outcomes

  1. Cumulative Illness Rating Scale for Geriatrics (CIRS-G)

    The CIRS (Cumulative Illness Rating Scale) score provides a relevant comparison of the medical burden and treatment outcomes in geriatric patients with variable and complex pathologies. The score ranges from 0: no problem to 4: very serious problem.

    Time frame: Months : 1, 2, 3 and 6

  2. Fried's frailty phenotype (FP)

    Frailty will be measured using Fried's frailty phenotype (FP), defined by exhaustion (EX), unexplained weight loss (WL), weakness (WK), sluggishness (SL) and low physical activity (LA). Three or more components define the frailty state, and one or two the pre-fragility state.

    Time frame: Months : 1, 2, 3 and 6

  3. level of physical activity

    Objective measures of PA (in MET-hours/week) via accelerometry (Actigraph GT3x, Pensacola, Florida, USA) and subjective measurements of PA (in METhours/week) using the e-Adult Physical Activity Questionnaire (EA SNA-EPIS, Université Jean Monnet, Saint-Etienne, France).

    Time frame: Months : 1, 2, 3 and 6

  4. level of sedentary lifestyle

    Objective measures of sedentary time (in h/d) via accelerometry (Actigraph GT3x, Pensacola, Florida, USA) and subjective measurements of sedentary behaviour (in hours/day) using the e-Adult Physical Activity Questionnaire (EA SNA-EPIS, Université Jean Monnet, Saint-Etienne, France).

    Time frame: Months : 1, 2, 3 and 6

  5. Nutritional status

    With the Mini Nutritional Assessment (MNA) and albumin analysis in g/l, a level \<35g/l: undernutrition, \<30g/l: severe undernutrition.

    Time frame: Months : 1, 2, 3 and 6

  6. Memory

    Mini-Mental State Examination (MMSE), which consists of 30 questions and is scored out of 30. The severity of memory impairment is considered mild if the score is above 20, moderate if the score is between 10 and 20, and severe if the score is below 10.

    Time frame: Months : 1, 2, 3 and 6

  7. Healthy quality of life

    With the EORTC-QLC30 version 3. This 30-item questionnaire assesses 15 dimensions of quality of life (5 functional scales: physical, cognitive, social, emotional or psychological and limitations in daily activities; 1 global health/quality of life scale; 9 symptom scales: fatigue, nausea and vomiting, pain, dyspnea, insomnia, loss of appetite, constipation and diarrhea, financial problems related to the disease).

    Time frame: Months : 1, 2, 3 and 6

  8. Fatigue

    With the Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F). The questionnaire consists of 13 questions, each of which corresponds to a Likert scale ranging from 0 to 4 (0 = not at all, 4 = very much). A score is obtained out of 52, with the higher the score, the less fatigued the patient is.

    Time frame: Months : 1, 2, 3 and 6

  9. Depression

    Using the Mini Geriatric Depression Scale (GDS) to 4 questions. If the score is greater than 1: high probability of depression, if the score is 0: high probability of no depression.

    Time frame: Months : 1, 2, 3 and 6

  10. Muscular strength

    Muscle strength (in kilogram) on the handgrip.

    Time frame: Months : 1, 2, 3 and 6

  11. Balance

    Assessed using the time (in seconds) taken to complete the Timed Up and Go (TUG). A time ≥ 20 seconds is associated with a risk of falling.

    Time frame: Months : 1, 2, 3 and 6

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Fayolle E, Baudot A, Chaneliere-Sauvant AF, Favier E, Rambaud F, Torche F, Celarier T, Hupin D. Effectiveness of a personalised 6-month programme on physical frailty in older patients treated for bladder or kidney cancer - FRAGECO program - multicenter, controlled, randomized study protocol. BMC Geriatr. 2026 Jun 12. doi: 10.1186/s12877-026-07821-z. Online ahead of print. PubMed 42286520 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 21 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Jul 18, 2025
StartActual
Dec 3, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Mar 2028
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07073703
Responsible party
Sponsor
First posted
Jul 18, 2025
Start date
Dec 3, 2025
Primary completion
Sep 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Dec 9, 2025

Study contacts

Evolène FAYOLLE, student
Contact
evolene.fayolle@chu-st-etienne.fr
(0)4 77 12 78 35 ext. +33
Amandine BAUDOT, Project Manager
Contact
amandine.baudot@chu-st-etienne.fr
(0)4 77 82 94 50 ext. +33
David HUPIN, MD
principal investigator · CHU de Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion